🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the effort against drug-resistant strains of the infection, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are escalating worldwide, with figures suggesting more than 82 million new cases each year. Especially elevated rates are observed in the African continent and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary development in the reality of rising global incidence, increasing antimicrobial resistance and the extremely scarce available drugs currently available.”

Health officials are deeply concerned about the surge in antibiotic-resistant strains. The WHO has designated it as a "high-priority threat". A tracking program found that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Gain Approval

Zoliflodacin, alternatively called a brand name, was approved by the American regulatory agency in mid-December for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists anticipate that specific application of this new drug will help slow the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This treatment, which is employed against urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to develop it.

“This milestone marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Testing Outcomes and Global Access

As per findings released by a major medical journal, zoliflodacin cured more than 90% of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which combines two antibiotics. The trial enrolled hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the rights to license and sell the drug in a wide range of developing nations.

Medical professionals directly involved have voiced hope. Having a single-dose, oral treatment like this is described as a "critical tool" for managing the epidemic. This is considered crucial to alleviate the strain of the disease for patients and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.